CTOs on the Move

US Micron

www.usmicron.com

 
US Micron is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.usmicron.com
  • 8704 Bourgade St Ste 200
    Lenexa, KS USA 66219
  • Phone: 913.888.7900

Executives

Name Title Contact Details

Similar Companies

21st Century Biochemicals

21st Century Biochemicals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kyowa Kirin

Kyowa Kirin Co., Ltd.

PhysIq

physIQ is the leader in digital medicine, dedicated to generating unprecedented health insight using continuous wearable biosensor data and advanced analytics. Its industry-leading, enterprise-ready cloud platform continuously collects and processes data from wearable biosensor using a deep portfolio of FDA-cleared analytics. The company has published one of the most rigorous clinical studies to date in digital medicine and are pioneers in developing, validating, and achieving regulatory approval of Artificial Intelligence-based analytics. With applications in both clinical trial support and healthcare, physIQ is transforming continuous physiological data into insight for health systems, payers, and pharmaceutical companies

Microline Surgical

Microline Surgical develops and manufactures high precision open and laparoscopic surgical instruments. Microline`s laparoscopic reposable instruments provide a cost-effective and eco-friendly solution for today`s OR. The MiFusion product line offers a broad spectrum of open and laparoscopic instruments used to seal and divide tissue utilizing proprietary Thermal Fusion technology.

Kyowa Hakko Kirin

Kyowa Kirin North America is a fully integrated specialty pharmaceutical company, where people work together to understand clinical needs and opportunities for innovation that can result in real advances for patients. Since 2018, the North American organization has received approval from the US Food and Drug Administration (FDA) to market 3 first-in-class medicines – achievements we share with the scientific, medical, and advocacy communities who contributed greatly to the success of these programs.